Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.5.2937

Gene Polymorphisms of OPRM1 A118G and ABCB1 C3435T May Influence Opioid Requirements in Chinese Patients with Cancer Pain  

Gong, Xiao-Di (Department of Oncology, Shanghai Third People's Hospital, School of Medicine, Shanghai Jiao Tong University)
Wang, Jiong-Yi (Department of Oncology, Shanghai Third People's Hospital, School of Medicine, Shanghai Jiao Tong University)
Liu, Feng (Department of Oncology, Shanghai Third People's Hospital, School of Medicine, Shanghai Jiao Tong University)
Yuan, Hai-Hua (Department of Oncology, Shanghai Third People's Hospital, School of Medicine, Shanghai Jiao Tong University)
Zhang, Wen-Ying (Department of Oncology, Shanghai Third People's Hospital, School of Medicine, Shanghai Jiao Tong University)
Guo, Yue-Hui (Department of Oncology, Shanghai Third People's Hospital, School of Medicine, Shanghai Jiao Tong University)
Jiang, Bin (Department of Oncology, Shanghai Third People's Hospital, School of Medicine, Shanghai Jiao Tong University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.5, 2013 , pp. 2937-2943 More about this Journal
Abstract
Backgrounds: Polymorphisms of OPRM1 A118G and ABCB1 C3435T have been suggested to contribute to inter-individual variability regarding pain sensitivity, opioid usage, tolerance and dependence and incidence of adverse effects in patients with chronic pain. This study aimed to investigate the association of both two polymorphisms with opioid requirements in Chinese patients with cancer pain. Methods: The genotypes of rs1799971 (OPRM1) and rs1045642 (ABCB1) were determined by PCR-RFLP and direct sequencing methods respectively in 112 patients with cancer-related pain. Comparisons between the different genotype or allele groups were performed with t-tests or one-way ANOVA tests, as appropriate. The potential relationship of allele number with opioid response was performed with a trend Jonckheere-Terpstra test. Results: In the 112 subjects, the frequencies of variant 118 G and 3435T allele were 38.4% and 37.9%, respectively. Significant higher 24h-opioid doses were observed in patients with GG (P=0.0004) and AG + GG (P=0.005) genotypes than the AA carriers. The dominant mutant 118G allele tended to be associated with progressively increasing 24h-opioiddoses (P=0.001). Compared with CC/CT, patients with ABCB1 TT genotype received higher 24h- and weight-surface area-adjusted-24h- opioids doses (P=0.057 and 0.028, respectively). Conclusions: The OPRM1 A118G single nucleotide polymorphism (SNP) is a key contributor for the inter-individual variability in opioidrequirements in Chinese cancer pain patients. This may possibly extend to the ABCB1 C3435T SNP.
Keywords
SNP; opioids requirements; cancer pain treatment; OPRM1 gene; ABCB1 gene;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al (2003). P-glycoprotein: from genomics to mechanism. Oncogene, 22, 7468-85.   DOI   ScienceOn
2 Baldissera VD, de Mattos AA, Coral GP, et al (2012). Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol, 11, 899-906.
3 Bayerer B, Stamer U, Hoeft A, et al (2007). Genomic Variations and Transcriptional Regulation of the Human Mu-Opioid Receptor Gene. Eur J Pain, 11, 421-7.   DOI   ScienceOn
4 Befort K, Filliol D, Decaillot FM, et al (2001). A Single Nucleotide Polymorphic Mutation in the Human Mu-Opooid Receptor Severely Impairs Receptor Signaling. J Biol Chem, 276, 3130-7.   DOI   ScienceOn
5 Beyer A, Koch T, Schroder H, et al (2004). Effect of the A118G polymorphism on binding affinity, potency and agonistmediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem, 89, 553-60.   DOI   ScienceOn
6 Bond C, LaForge KS, Tian M, et al (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A, 95, 9608-13.   DOI
7 Campa D, Gioia A, Tomei A, et al (2008). Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther, 83, 559-66.   DOI   ScienceOn
8 Chen CJ, Chin JE, Ueda K, et al (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47, 381-9.   DOI   ScienceOn
9 Elliott AM, Smith BH, Penny KI, et al (1999). The epidemiology of chronic pain in the community. Lancet, 354, 1248-52.   DOI   ScienceOn
10 Fernandez Robles CR, Degnan M, Candiotti KA(2012). Pain and genetics. Curr Opin Anaesthesiol, 25, 444-9.   DOI
11 Fujita K, Ando Y, Yamamoto W, et al (2010). Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol, 65, 251-8.   DOI
12 Haerian BS, Haerian MS (2013). OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics, 14, 813-24.   DOI   ScienceOn
13 Hamabe W, Maeda T, Fukazawa Y, et al (2006). P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav, 85, 629-36.   DOI   ScienceOn
14 Huang P, Chen C, Mague SD, et al (2012). A common single nucleotide polymorphism A118G of the $\mu$ opioid receptor alters its N-glycosylation and protein stability. Biochem J, 441, 379-86.   DOI
15 Hirota T, Ieiri I, Takane H, et al (2003). Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos, 31, 677-80   DOI   ScienceOn
16 Hoehe MR, Kopke K, Wendel B, et al (2000). Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet, 9, 2895-908.   DOI   ScienceOn
17 Hoffmeyer S, Burk O, von Richter O, et al (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 97, 3473-8.   DOI   ScienceOn
18 Hung CC, Chen CC, Lin CJ, et al (2008). Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics, 18, 390-402.   DOI
19 Ikeda K, Ide S, Han W, et al (2005). How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci, 26, 311-7.   DOI   ScienceOn
20 Kasai S, Hayashida M, Sora I, et al (2008). Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch Pharmacol, 377, 269-81.   DOI
21 Kasai S, Ikeda K (2011). Pharmacogenomics of the human $\mu$-opioid receptor. Pharmacogenomics, 12, 1305-20.   DOI   ScienceOn
22 Kimchi-Sarfaty C, Oh JM, Kim IW, et al (2007). A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525-8.   DOI   ScienceOn
23 Leschziner G, Zabaneh D, Pirmohamed M, et al (2006). Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics, 16, 439-50.   DOI
24 Klepstad P, Fladvad T, Skorpen F, et al (2011). Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain, 152, 1139-45.   DOI   ScienceOn
25 Kosarac B, Fox AA, Collard CD (2009). Effect of genetic factors on opioid action. Curr Opin Anaesthesiol, 22, 476-82.   DOI   ScienceOn
26 Landau R, Kern C, Columb MO, et al (2008). Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain, 139, 5-14.   DOI   ScienceOn
27 Li D, Zhang GL, Lou YQ, et al (2007). Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther, 32, 89-95.   DOI   ScienceOn
28 Lloret Linares C, Hajj A, Poitou C, et al (2011). Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population. Obes Surg, 21, 1257-64.   DOI   ScienceOn
29 Lotsch J, Geisslinger G (2006). Relevance of frequent muopioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J, 6, 200-10.   DOI   ScienceOn
30 Lotsch J, Skarke C, Wieting J, et al (2006). Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther, 79, 72-89.   DOI   ScienceOn
31 Mealey KL (2008). Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics. Vet Parasitol, 158, 215-22.   DOI   ScienceOn
32 Shabalina SA, Zaykin DV, Gris P, et al (2009). Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet, 18, 1037-51.   DOI   ScienceOn
33 Oertel BG, Schmidt R, Schneider A, et al (2006). The mu-opioid receptor gene polymorphism 118A>G depletes alfentanilinduced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics, 16, 625-36.   DOI
34 Reyes-Gibby CC, Shete S, Rakvåg T, et al (2007). Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain, 130, 25-30.   DOI   ScienceOn
35 Salama NN, Yang Z, Bui T, et al (2006). MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci, 95, 2293-308.   DOI   ScienceOn
36 Sia AT, Lim Y, Lim EC, et al (2008). A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology, 109, 520-6.   DOI   ScienceOn
37 Sia AT, Sng BL, Lim EC, et al (2010). The influence of ATPbinding cassette sub-family B member -1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study. Int J Obstet Anesth, 19, 254-60.   DOI   ScienceOn
38 Smith K, Hopp M, Mundin G, et al (2012). Low absolute bioavailability of oral naloxone in healthy subjects. J Clin Oncol, 19, 2542-54.
39 Tan EC, Lim EC, Teo YY, et al (2009). Ethnicity and OPRM variant independently predict pain perception and patientcontrolled analgesia usage for post-operative pain. Mol Pain, 5, 32.   DOI   ScienceOn
40 Tan EC, Tan CH, Karupathivan U, et al (2003). Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport, 14, 569-72.   DOI   ScienceOn
41 Tang K, Wong LP, Lee EJ, et al (2004). Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Mol Genet, 13, 783-97.   DOI   ScienceOn
42 Uhl GR, Sora I, Wang Z (1999). The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A, 96, 7752-55.   DOI
43 Wang D, Johnson AD, Papp AC, et al (2005). Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics, 15, 693-704.   DOI   ScienceOn
44 Wang D, Quillan JM, Winans K, et al (2001). Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem, 276, 34624-30.   DOI   ScienceOn
45 Wang JB, Johnson PS, Persico AM, et al (1994). Human mu opiate receptor: cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett, 338, 217-22.   DOI   ScienceOn
46 Zhou B, Wang J, Yan Z, et al (2012). Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE. Radiology, 262, 1014-21.   DOI
47 Zhou SF, Zhou ZW, Li CG, et al (2007). Identification of drugs that interact with herbs in drug development. Drug Discov Today, 12, 664-73.   DOI   ScienceOn